Similar articles

• [Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease].

  Joly D. Joly D. Med Sci (Paris). 2011 Mar;27(3):249-51. doi: 10.1051/medsci/2011273249. Epub 2011 Mar 30. Med Sci (Paris). 2011. PMID: 21447293 French. No abstract available.
• Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

  Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Serra AL, et al. N Engl J Med. 2010 Aug 26;363(9):820-9. doi: 10.1056/NEJMoa0907419. Epub 2010 Jun 26. N Engl J Med. 2010. PMID: 20581391 Clinical Trial.
• [Autosomal dominant polycystic kidney disease].

  Horie S. Horie S. Nihon Jinzo Gakkai Shi. 2011;53(1):6-9. Nihon Jinzo Gakkai Shi. 2011. PMID: 21370570 Review. Japanese. No abstract available.
• Everolimus in patients with autosomal dominant polycystic kidney disease.

  Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU. Walz G, et al. N Engl J Med. 2010 Aug 26;363(9):830-40. doi: 10.1056/NEJMoa1003491. Epub 2010 Jun 26. N Engl J Med. 2010. PMID: 20581392 Clinical Trial.
• Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.

  Wüthrich RP, Kistler AD, Serra AL. Wüthrich RP, et al. Transplant Proc. 2010 Nov;42(9 Suppl):S44-6. doi: 10.1016/j.transproceed.2010.07.008. Transplant Proc. 2010. PMID: 21095452 Review.